Kornimate/medical-research-clean huggingface dataset:
stretching exercises versus thermotherapy on restless legs syndrome symptoms

Conditions: Muscle Disorder

Summary: to compare the effects of stretching exercises versus thermotherapy on rls symptoms and sleep quality among pregnant women. research hypotheses: * pregnant women who perform leg stretching exercises exhibit lower rls symptoms severity and pain level than those who applied thermotherapy. * pregnant women who perform leg stretching exercises exhibit higher sleep quality than those who applied thermotherapy.

a quasi-experimental study was carried out at the antenatal outpatient clinic of xxxx. a sample of 60 pregnant women was randomly assigned to two groups. one group was instructed to perform stretching exercises daily for one week, and the other group applied thermotherapy. they rated their rls symptoms, pain level, and sleep quality at baseline and after receiving interventions. a convenience sampling of 60 pregnant women who fulfilled the following inclusion criteria was recruited: suffering from rls according to the irlssg criteria during the third-trimester of a singleton pregnancy; rated restlessness severity greater than ten on the rls rating scale, and compliant with an iron supplement. while, women who had a high-risk pregnancy, e.g., preeclampsia, diabetes, and placenta previa as well as had leg cramps, periodic limb movement disorder, leg edema, myalgia, peripheral neuropathy, leg injuries, and anxiety were excluded from the study. initially, the researchers approached the pregnant women of both groups in the waiting area of the antenatal clinic, established rapport, and collected the socio-demographic data and current pregnancy profile, moreover, baseline rls symptoms severity, pain, and women's sleep quality were assessed. interventions for the stretching exercises group; the researchers explained to the women how to perform the stretching exercises through different visual materials like videos \& pictures, provided a demonstration of each step, and emphasized that they could perform this exercise at any comfortable position, standing, sitting, or dorsal. for the thermotherapy group, women were instructed to warm the water to 43-47 c° using a water thermometer or test it with the inner aspect of their wrists. they are also advised to avoid using too hot or too cold water. then immerse their legs for 20 minutes in the warm water at a height where the water level can reach their knees. the researchers emphasized that the procedure should be done every night for one week. for both groups, the intensity of rls and pain severity of pregnant women of the two groups were reassessed after the first session.

Eligibility criteria:
inclusion criteria: * had singleton pregnancy * during the third-trimester * rated restlessness severity greater than ten on the rls rating scale * compliant with an iron supplement. exclusion criteria: * had a high-risk pregnancy * periodic limb movement disorder * leg edema * myalgia * peripheral neuropathy * leg injuries * anxiety

Keywords: muscle stretching exercises thermotherapy restless legs syndrome pain sleep quality pregnant women
phase 1 study assessing the safety and tolerability of ctx-4430 in cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to assess the safety and tolerability of multiple oral doses of ctx-4430 when administered to cystic fibrosis (cf) patients once-daily (qd) for 15 days.this study will include two dose levels. for each dose level, blood samples will be collected for exploratory pk and pd assay validation. in addition, sputum will be collected for exploratory biomarker analysis. following multiple dose administration, pulmonary function and exploratory lung clearance index (lci) measurements will be taken.


Eligibility criteria:
inclusion criteria: 1. adult male or female, 18 to 55 years of age (inclusive) at the time of screening. 2. confirmed diagnosis of cf based on the following: positive sweat chloride or sodium value ≥ 60 meq/l, and/or genotype with two identifiable mutations consistent with cf, accompanied by one or more clinical features consistent with the cf phenotype or a diagnosis of cf made by a specialist in this condition. 3. in the judgment of the principal investigator (pi), the patient is medically stable with no change in symptoms, medication, or with clinical laboratory results that in pi opinion are compatible with the diagnosis of either cf or a complication thereof and are judged acceptable for inclusion. 4. body mass index (bmi) ≥ 17.0 (kg/m2). 5. non-tobacco/nicotine-containing product user for a minimum of 6 months prior to the first study drug administration. 6. forced expiratory volume (fev1) of \>50% and \<90% of predicted at screening. 7. must agree to use adequate method of contraception. exclusion criteria: 1. patient has displayed any significant clinical/laboratory/radiological/spirometric sign of unstable or unexpectedly deteriorating respiratory disease within 30 days prior to the first study drug administration. 2. history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease that depart from the patient's usual baseline level of health as a patient with cf. 3. has a history of lung transplantation. 4. history or presence of alcoholism or drug abuse within 2 years prior to the first study drug administration. 5. personal or family history of prolonged qt syndrome; or a qtc interval \>430 msec (males) or \>450 msec (females) using bazett's formula (qtcb) or deemed clinically significant by the pi. 6. sitting blood pressure is less than 90/40 mmhg or greater than 140/90 mmhg, unless deemed clinically insignificant by the pi. 7. pulse is higher than 100 b.p.m or lower than 50 b.p.m. unless deemed clinically insignificant by the pi. 8. failure to satisfy the pi of fitness to participate for any other reason. 9. in the judgment of the pi, clinically significant hemoptysis (\>30 cc per episode) within the last 180 days.
effectiveness of the upatient platform in prophylactic treatment in hemophilia

Conditions: Haemophilia

Summary: research project whose main objective is to evaluate the use of a technology platform (upatient) to register the prophylactic treatment of patients with hemophilia treated in different hematology and hemotherapy services of several hospitals in spain.

the data obtained in this project will identify the level of compliance to the pharmacological treatment of patients with hemophilia prophylaxis. they will use different psychosocial questionnaires based on scientific evidence and the reliability of these, as well as its specific design for patients with hemophilia. clinical data were also obtained regarding the joint of patients participating in the study state.

Eligibility criteria:
inclusion criteria: * patients diagnosed with hemophilia a or b * patients over 13 years old * patients on prophylactic treatment. exclusion criteria: * patients who do not sign the informed consent document * patients who do not make domiciliary self-treatment * patients who do not have good adhesion to prophylactic treatment

Keywords: haemophilia adherence prophylaxis treatment quality of life illness behavior veritas-pro questionnaire upatient
in vivo glycocalyx as predictor of complications after cardiac surgery

Conditions: Endothelial Dysfunction; Cardiovascular Diseases; Surgery

Summary: cardiac surgery has been described as altering endothelium structure and function, notably because of the use of cardiac-pulmonary bypass (cpb). among the endothelial structure, glycocalyx, the thin layer recovering the endothelial surface, may be altered by the inflammatory process and probably the modification of flow during cpb. endothelial and glycocalyx integrity are essential for vascular function and glycocalyx destruction is associated with organ failure and mortality. on the other hand, a chronic alteration of glycocalyx is observed in many diseases such as diabetes, hypertension or chronic kidney failure, all pathologies frequently observed in patients benefiting grom cardiac surgery. thus the preoperative alteration of glycocalyx may be associated with postoperative organ failure.


Eligibility criteria:
inclusion criteria: * all patients benefiting from a cardiac surgery with cardio-pulmonary bypass exclusion criteria: * impossibility to carry out the measurement by glycocheck device * refusal to participate
ebus-tbna versus ebus-tbnb

Conditions: Mediastinal Lymphadenopathy; Hilar Lymphadenopathy; Carcinoma; Lymphoma; Sarcoidosis; Mycobacterial Disease

Summary: a prospective diagnostic clinical study randomising patients undergoing endobronchial ultrasound guided transbronchial needle aspiration (ebus-tbna) of enlarged mediastinal and hilar lymph nodes to have sampling using the usual ebus-tbna needle or a novel biopsy forceps (ebus-tbnb). the study aims to establish whether the use of ebus-tbnb can significantly increase the diagnostic yield over ebus-tbna, without an increase in complication rates.


Eligibility criteria:
inclusion criteria: * scheduled for ebus-tbna as part of clinical care * lymph nodes larger than 10mm in diameter * age \> 18 years * able to provide written informed consent exclusion criteria: * contraindications for needle or forceps biopsy (e.g. coagulopathy, anticoagulation, thrombocytopenia) * inability to obtain informed consent

Keywords: endobronchial ultrasound transbronchial needle aspiration transbronchial biopsy forceps mediastinal lymphadenopathy hilar lymphadenopathy
efficacy of topical pimecrolimus in the treatment of pityriasis alba

Conditions: Pityriasis Alba

Summary: pityriasis alba (pa) is a common benign skin disorder, that usually affects children and adolescents of darker phototypes. a history of atopic dermatitis is a well-known risk factor, and pa may be a minor manifestation of atopic dermatitis, although it can occur in nonatopic individuals as well. the objective is to evaluate the effect of topical pimecrolimus in the treatment of treatment of pa

background and rationale: pityriasis alba (pa) is a common benign skin disorder, that usually affects children and adolescents of darker phototypes. pa usually manifests as erythematous lesions followed by smooth scales with residual characteristic pruritic or non-pruritic ill-defined hypopigmented patches, that typically occur on the upper part of the body, especially the face. a history of atopic dermatitis is a well-known risk factor, and pa may be a minor manifestation of atopic dermatitis, although it can occur in nonatopic individuals as well. it is thought to represent nonspecific dermatitis with residual post-inflammatory hypopigmentation. sun exposure is a triggering and accentuating factor. pa is a common reason for dermatologic consultation due to its chronic course, frequent relapses and cosmetic appearance. spontaneous healing occurs in several months to few years, therefore impacting the quality of life. emollients and mild-potency topical steroids are the mainstay of treatment, with a potential risk of skin atrophy and hypopigmentation. pimecrolimus is a topical calcineurin inhibitor that prevents t-cell activation, approved for the treatment of atopic dermatitis, and proved efficacious for seborrheic dermatitis, without having the potential adverse effects of topical corticosteroids. tacrolimus 0.1% ointment, another calcineurin inhibitor is an effective and safe treatment for pa, a similar efficacy of calcitriol and tacrolimus was shown after 9 weeks of treatment. an exploratory study evaluated the efficacy of pimecrolimus cream in the treatment of pa. to the best of our knowledge there is no randomized placebo-controlled trial in the literature proving the efficacy of pimecrolimus in pa. objective: to evaluate the effect of topical pimecrolimus in the treatment of treatment of pa hypothesis: pimecrolimus is an efficacious, well-tolerated and safe treatment for pityriasis alba. trial design: a randomized placebo-controlled double blinded trial establishing the superiority of topical pimecrolimus 1% over placebo.

Eligibility criteria:
inclusion criteria: * pityriasis alba patients confirmed by a board certified dermatologist * age over 2 years * written informed consent signed by the patients or the legal guardians of patients younger than 18 years in the native language (arabic) exclusion criteria: * other concomitant dermatosis (except atopic dermatitis) * use of topical steroids, or topical agents other than emollients and sunscreen, in the last 4 weeks * known allergy to pimecrolimus * pregnant and nursing women

Keywords: pityriasis alba treatment topical calcineurin inhibitor
evaluation of cognitive state in senior subjects using neurosteer eeg system

Conditions: Mild Cognitive Impairment

Summary: this is an observational study. patients who fulfill all inclusion criteria and none of the exclusion criteria will be enrolled in the study, be neurologically evaluated and will go through eeg recordings while listening to an auditory cognitive assessment tool. eeg recordings will be analyzed using proprietary computational analyses.

one of the major problems in the prevention and treatment of neurological disorders, is the lack of cost effective and reliable tools to assess neurodegeneration on a large scale at a very early stage. although current imaging methods give a clear image of the brain atrophy involved in neurodegenerative disorders, there are deficiencies prohibiting their usage for prevention-scanning of large high-risk population such as high price, long set-up time and the need for trained personnel to conduct the test. therefore, the development of a reliable tool to assess brain neurodegeneration, associated with cognitive decline independent of personal interpretation and/or variance between clinicians and between medical facilities would be highly valuable. this tool would allow the healthcare team to make appropriate treatment decisions that could aid in neurodegenerative disease prevention. the neurosteer system provides objective neurological biomarkers using a wearable easy-to-use affordable system. the system facilitate the capture and interpretation of eeg data with only a single patch of electrodes, attached on the subject's forehead. neurosteer examination includes completing auditory tasks while measuring brain activity with the device. the data is analyzed using machine learning methods to produce biomarkers, enabling a report of the patient's activity in real time and offline. the examination is easy to preform and can be conducted in every clinic or in patients' homes. in this study, clinical staff will identify potential subjects and will examine the eligibility of subject according to inclusion and exclusion criteria. research staff will inform the patient on study's objective and design. patients will sign the informed consent form (icf). research staff will set up an initial session using the neurosteer system. in this session the patient will perform auditory cognitive assessment tasks. the patient will be re-examined in the same experimental setting over the next 7 days and at least 1 day later. level of cognition will be assessed by the neurosteer technology.

Eligibility criteria:
inclusion criteria: * men and women over the age of 50. * mmse ≥ 24. * patient is able to collaborate. * no other cognitive comorbidity. * no seizure events. exclusion criteria: * mmse \< 24. * any verbal or non-verbal form of objection from patient or form patient's family member or significant other. * presence of several cognitive comorbidity. * damage to integrity of scalp and/or skull. * skin irritation in the facial and forehead area. * significant hearing impairments. * history of drug abuse.

Keywords: cognition neurology eeg neurosteer
ultrasound-guided axillary or infraclavicular nerve block for upper limb surgery

Conditions: Upper Extremity; Orthopedic Surgery; Trauma; Forearm Injuries; Nerve Block

Summary: this study aims to detect differences in onset time of brachial plexus (i.e., arm) anesthesia using two different nerve block techniques. using ultrasound guidance, axillary (i.e., at the armpit) and infraclavicular (i.e., below the collarbone) blocks will be performed to patients undergoing upper limb surgery. the investigators will analyze how long it takes for anesthesia to be adequate for pain-free surgery, thus determine the optimal technique for this kind of surgery.

real-time ultrasound guidance has substantially reduced the risk of pneumothorax and/or vascular puncture during infraclavicular brachial plexus blocks. the role of this technique has thus been expanded to overlap those procedures for which an axillary nerve block would be commonly considered as first choice. a reference block for upper limb surgery thanks to its safety profile and clinical efficacy, the axillary approach may be more painful or unpleasant for some patients. the investigators aim to determine possible differences in onset time and patient acceptance between the two techniques.

Eligibility criteria:
inclusion criteria: * asa physical status class \<4 * scheduled upper extremity orthopedic surgery exclusion criteria: * psychiatric or cognitive disorder * allergy to study drugs * contraindication to nerve block at the assigned site

Keywords: anesthesia upper extremity nerve block ultrasound brachial plexus
reproductive hormones and pre-clinical cardiovascular disease (cvd) in women

Conditions: Heart Disease

Summary: heart disease is not just the number one killer of women, it is also a leading cause of disability. while it is generally believed that heart disease in women is a disease of old age, the stark reality is that heart disease is responsible for more deaths than breast cancer at all ages. also, when young women develop heart disease, they are more likely to die or become disabled than their male peers. identifying women at risk for heart disease is an important step toward reducing the impact of this disease. although women can develop heart disease at any age, most women show signs and symptoms of disease about 10 years after men. for years, it has been thought that the reason for this lag is that women's hearts are protected by estrogen, and that when women go through menopause and lose their natural estrogen, they also lose their protection from heart disease. it has been assumed that if estrogen is replaced then protection will continue. these assumptions have not been proven. in fact, three large, randomized trials have shown no benefit from hormone replacement therapy in women known to have heart disease, and in fact have shown that hormone replacement may be harmful. to better understand the role of hormones and heart disease, the investigators propose to look at markers of heart disease in healthy women and compare this to their natural hormone levels. one of the markers known to be related to heart disease is carotid artery intima-medial thickness (c-imt) which can be measured by creating an ultrasound picture of an artery in the neck. the investgators will use c-imt scans and serum blood samples from women in the nih-sponsored los angeles atherosclerosis study (laas), a large epidemiologic study that followed participants for 8 years. the proposed study will use risk factor information, serum samples and c-imt scans collected from the female participants (about 269 women) over the 8 years of follow-up. the total sample size is 269 subjects, each of whom donated 3 blood specimens for the laas study. this research will examine those specimens (800 in total). it will also measure other markers of heart disease, including inflammation (hscrp) and diabetes (insulin and glucose). all information has been obtained and there will be no need to collect additional information from participants nor additional blood specimens.


Eligibility criteria:
inclusion criteria: * healthy * females * 40-60 years of age

Keywords: reproductive hormones
added value of a small camera (iriscope) in the endoscopic diagnosis of peripheral lung nodules and masses

Conditions: Pulmonary Nodule, Solitary

Summary: since the beginning of lung screening program in the different countries around the world by chest ct scan, numerous lung nodules and masses of unknown etiology are diagnosed. usually, the pathological diagnosis is obtained by bronchoscopy. however, peripheral bronchi cannot be seen after the fifth bronchial division as the diameter of the broncoscope is greated than the diameter of the bronchi. therefore, the iriscope was developed. it consists in a thin catheter with a mini-camera at its distal extremity. the aime of this study is to evaluate the diagnostic yield of bronchoscopy guided by iriscope in the setting of peripheral lung nodules and masses supect of malignancy, to compare the iriscope to endobronchial radial ultrasonography (which is a validated technique to guide bronchoscopy in the setting of peripheral lung nodules and masses) and to evaluate the added value on the diagnostic yield by combining these 2 techniques.


Eligibility criteria:
inclusion criteria: * lung nodules or masses suspect of malignancy with a diameter between 2 and 5 centimeters exclusion criteria: * any contraindication to general anesthesia * coagulopathy
effect of different working conditions on risk factors in dentists versus trainers

Conditions: Healthy

Summary: the aim of the study is to validate the sanitary consequences of dental studies respectively the longtime executed profession. in comparison to this cohort we will also check a collective of subjects with an optimum of physical activity.


Eligibility criteria:
inclusion criteria: * healthy * age 19-30 years(longitudinal) * 55-60 years (crosssectional) * dentists * trainers exclusion criteria: * pregnant * cvd * medication; and * diseases affecting body composition

Keywords: risk factors metabolic syndrome dentists trainers healthy subjects students seniors
the role that peroral endoscopic myotomy (poem) could play in the treatment of achalasia

Conditions: Achalasia

Summary: based on the work of the doctors at the mayo clinic rochester, a new technique for a less invasive treatment for achalasia has been developed. the purpose of this study is to decide the role this less invasive treatment (peroral endoscopic myotomy) has in the treatment of patient's with achalasia.


Eligibility criteria:
inclusion criteria: * patients between the ages of 18 and 80 with achalasia diagnosed by a combination of compatible symptoms, barium esophagography and high resolution manometry. exclusion criteria: * patients who are poor surgical risks, have had previous treatment for achalasia or esophageal or gastric surgery, have an epiphrenic diverticulum or are unwilling to be followed in the protocol. * female patients are eligible if they are not pregnant or lactating and ne of the following criteria is met: * the patient is surgically sterile (by means of hysterectomy/bilateral tubal ligation) * the patient is at least one year postmenopausal (no menses for 12 months). * the patient is using a highly effective method of contraception, if childbearing potential, and has a negative urine human chorionic gonadotropin beta subunit (ß hcg) pregnancy test result during screening, and prior to trial drug administration. * highly effective methods of birth control are defined as those which result in a low failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some iuds, sexual abstinence or vasectomized partner. * withdrawal, single- or double barrier methods (including condoms) and rhythm methods are not acceptable methods of contraception for the purposes of this clinical trial due to the high incidence of contraceptive failures with these methods. * vulnerable populations, such as those with diminished mental acuity, will be excluded.

Keywords: less invasive treatment for achalasia